摘要
目的:分析乳癖消、小金丸、乳增宁治疗乳腺增生的经济学效果。方法:采用成本-效果分析法,以165例乳腺增生患者为对象,对3种治疗方案"[乳癖消"组(A组)、"小金丸"组(B组)、"乳增宁"组(C组)]进行经济学评价。结果:3种治疗方案总有效率分别为84.7%、90.2%、90.9%,成本分别为459、1350、639元,成本-效果比分别为541.91、1496.67、702.97。结论:乳增宁为治疗乳腺增生的较佳方案。
OBJECTIVE：To study economic effects of 3 kinds of Chinese patent medicine Rupixiao, Xiaojinwan and Ruzengning, in the treatment of breast hyperplasia.METHODS：Cost-effectiveness analysis was used to evaluate the economic effects of 3 kinds of therapeutic regimens with 165 patients as objects[＂Rupixiao＂ group（group A）, ＂Xiaojinwan＂ group（group B）, ＂Ruzengning＂ group（group C）].RESULTS：The total effective rates of 3 kinds of therapeutic regimens were 84.7%, 90.2% and 90.9%; the costs were 459 yuan, 1 350 yuan and 639 yuan; cost-effectiveness ratio were 541.91, 1 496.67 and 702.97, respectively.CONCLUSION：Ruzengning therapy is best in the treatment of breasr hyperplasia.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第40期3818-3819,共2页
China Pharmacy
关键词
乳腺增生
成本-效果分析
药物经济学
乳增宁
Breast hyperplasia
Cost-effectiveness analysis
Pharmacoeconomics
Ruzengning
